Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02748837 · ClinicalTrials.gov registry record · Phase 1
A Study of ERY974 in Patient With Advanced Solid Tumors
A Phase 1 study, sponsored by Chugai Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02748837: Completed Phase 1 study, sponsored by Chugai Pharmaceutical.
NCT02748837 is a Phase 1 study that has completed, run by Chugai Pharmaceutical. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02748837, a Phase 1 study, has completed, sponsored by Chugai Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tumors until unacceptable toxicity or disease progression.
Primary Outcome
Determination of dose-limiting toxicities (DLT)
Interventions
- DRUG ERY974
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-08 |
| Est. Completion | 2019-08 |
| Phase | Phase 1 |
What the finished NCT02748837 record still lists
NCT02748837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 1 intervention - of which ERY974 is the first listed.
NCT02748837 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02748837 about?
NCT02748837 is a clinical study titled "A Study of ERY974 in Patient With Advanced Solid Tumors". This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tum...
What is the current status of trial NCT02748837?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2016-08. Estimated completion is 2019-08.
What interventions are being tested in trial NCT02748837?
The interventions under investigation include: ERY974 (DRUG).
Who is sponsoring clinical trial NCT02748837?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02748837's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia